Lauer Matthias E, Maurer Reto, Paepe Anne T De, Stillhart Cordula, Jacob Laurence, James Rajesh, Kojima Yuki, Rietmann Rene, Kissling Tom, van den Ende Joost A, Schwarz Sabine, Grassmann Olaf, Page Susanne
Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.
Pharmaceutical Research and Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.
Pharmaceutics. 2018 May 19;10(2):58. doi: 10.3390/pharmaceutics10020058.
Hot-melt extrusion is an option to fabricate amorphous solid dispersions and to enhance oral bioavailability of poorly soluble compounds. The selection of suitable polymer carriers and processing aids determines the dissolution, homogeneity and stability performance of this solid dosage form. A miniaturized extrusion device (MinEx) was developed and Hypromellose acetate succinate type L (HPMCAS-L) based extrudates containing the model drugs neurokinin-1 (NK1) and cholesterylester transfer protein (CETP) were manufactured, plasticizers were added and their impact on dissolution and solid-state properties were assessed. Similar mixtures were manufactured with a lab-scale extruder, for face to face comparison. The properties of MinEx extrudates widely translated to those manufactured with a lab-scale extruder. Plasticizers, Polyethyleneglycol 4000 (PEG4000) and Poloxamer 188, were homogenously distributed but decreased the storage stability of the extrudates. Stearic acid was found condensed in ultrathin nanoplatelets which did not impact the storage stability of the system. Depending on their distribution and physicochemical properties, plasticizers can modulate storage stability and dissolution performance of extrudates. MinEx is a valuable prototyping-screening method and enables rational selection of plasticizers in a time and material sparing manner. In eight out of eight cases the properties of the extrudates translated to products manufactured in lab-scale extrusion trials.
热熔挤出是制备无定形固体分散体和提高难溶性化合物口服生物利用度的一种方法。合适的聚合物载体和加工助剂的选择决定了这种固体剂型的溶出度、均匀性和稳定性。开发了一种小型挤出装置(MinEx),并制备了含有模型药物神经激肽-1(NK1)和胆固醇酯转移蛋白(CETP)的基于醋酸羟丙甲纤维素琥珀酸酯L型(HPMCAS-L)的挤出物,添加了增塑剂,并评估了它们对溶出度和固态性质的影响。用实验室规模的挤出机制造了类似的混合物,以便进行面对面比较。MinEx挤出物的性质与用实验室规模挤出机制造的挤出物的性质广泛相似。增塑剂聚乙二醇4000(PEG4000)和泊洛沙姆188均匀分布,但降低了挤出物的储存稳定性。发现硬脂酸凝聚成超薄纳米片,这对体系的储存稳定性没有影响。根据增塑剂的分布和物理化学性质,它们可以调节挤出物的储存稳定性和溶出性能。MinEx是一种有价值的原型筛选方法,能够以节省时间和材料的方式合理选择增塑剂。在所有八个案例中,挤出物的性质都与实验室规模挤出试验中制造的产品相似。